EPCAM and neoplasm: Several protocols and platforms have been developed for their isolation, with two distinct approaches: label-free strategies, including the use of red blood cell (RBC) lysis buffers, size selection (ISET, Rarecells, Inc. USA), Parsortix (Angle plc, CA, USA), CanPatrol (SurExam, China), density gradient centrifugation, etc., or label-dependent strategies, including negative selection (mainly using CD45 exclusion) or positive selection with a variety of markers depending on the tumour type (EpCAM being the most widely used).